Tetraphase Selects SHYFT to Support Data and Analytics for Launch
SHYFT Analytics, recently acquired by Medidata Solutions to create its Intelligent Platform for Life Sciences, announced Tetraphase Pharmaceuticals has selected its platform to support the commercial launch of eravacycline, its antibiotic candidate developed to address multidrug-resistant bacteria.
Eravacycline is currently being developed for the treatment of complicated intra-abdominal infections (cIAI). Pending a decision by the U.S. Food and Drug Administration, Tetraphase plans to launch the broad-spectrum antibiotic in the U.S. later in 2018.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
